Hepatitis B

What is Hepatitis B?

Hepatitis B is a viral infection that attacks the liver and can cause both acute (short-term) and chronic (long-term) disease. The infection is caused by the hepatitis B virus (HBV), which is transmitted through contact with infected blood or other body fluids. Hepatitis B affects people of all ages worldwide, with an estimated 296 million people living with chronic hepatitis B infection globally. While acute hepatitis B often resolves on its own, chronic infection can lead to serious liver complications including cirrhosis and liver cancer.

Key statistics

Global prevalence	296 million people with chronic infection (2019)
Annual deaths	820,000 deaths annually from hepatitis B complications
Mother-to-child transmission	90% risk without prevention measures
Vaccine effectiveness	95% effective in preventing infection

Symptoms

Many people with hepatitis B, especially children, may have no symptoms initially. When present, symptoms include: fatigue, abdominal pain, nausea, vomiting, joint pain, jaundice, dark urine, clay-colored stools.

Early symptoms (acute infection): Fatigue and weakness often appear first, followed by loss of appetite and mild abdominal discomfort. Low-grade fever and muscle aches may also occur.

Common symptoms: Nausea and vomiting develop as the infection progresses, along with pain in the upper right abdomen where the liver is located. Joint pain and skin rashes may also appear.

Serious symptoms: Jaundice (yellowing of skin and eyes) indicates significant liver involvement. Dark urine and light-colored stools accompany jaundice. Severe fatigue and confusion may signal liver failure in advanced cases.

Causes and risk factors

Hepatitis B is caused by infection with the hepatitis B virus (HBV), a DNA virus that specifically targets liver cells. The virus spreads through contact with infected blood, semen, or other body fluids.

Primary risk factors include: Unprotected sexual contact with infected individuals, sharing needles or drug equipment, occupational exposure to blood (healthcare workers), receiving blood transfusions in areas without adequate screening, and being born to a mother with hepatitis B. People living in areas with high hepatitis B prevalence, including parts of Africa, Asia, and the Pacific Islands, face increased risk. Men who have sex with men, people with multiple sexual partners, and individuals with HIV or hepatitis C co-infection also have elevated risk.

Prevention

The hepatitis B vaccine is the most effective prevention method, providing 95% protection when administered as a complete series. The World Health Organization recommends universal infant vaccination, with the first dose given within 24 hours of birth. Adults at high risk should also receive vaccination.

Additional prevention strategies include: Practicing safe sex by using barrier protection, never sharing needles or personal items like razors and toothbrushes, ensuring proper sterilization of medical and dental equipment, and screening blood products before transfusion. Healthcare workers should follow universal precautions and receive post-exposure prophylaxis when indicated. Pregnant women should be tested for hepatitis B, and infants born to infected mothers should receive both vaccine and immunoglobulin within 12 hours of birth.

Complications

Without proper management, chronic hepatitis B can lead to serious liver complications. Approximately 15-25% of people with chronic infection develop severe liver disease.

Major complications include: Cirrhosis (liver scarring) develops in 20-30% of chronically infected individuals, potentially progressing to liver failure. Hepatocellular carcinoma (liver cancer) occurs at rates 100 times higher in people with chronic hepatitis B compared to uninfected individuals. End-stage liver disease may require liver transplantation. Co-infection with hepatitis C or HIV accelerates disease progression. Kidney disease, blood vessel inflammation, and other extrahepatic manifestations can also occur.

Diagnosis

Hepatitis B diagnosis relies on specific blood tests that detect viral markers and assess liver function. Initial screening typically includes hepatitis B surface antigen (HBsAg) testing.

Diagnostic tests include: HBsAg (hepatitis B surface antigen) indicates active infection when positive. Anti-HBs (surface antibody) shows immunity from vaccination or recovery. Anti-HBc (core antibody) indicates past or current infection. HBeAg and anti-HBe help determine infectivity and disease activity. Hepatitis B DNA quantification measures viral load. Liver function tests including ALT, AST, and bilirubin assess liver damage. Imaging studies like ultrasound, CT, or MRI evaluate liver structure. Liver biopsy may be performed to determine the extent of liver damage and guide treatment decisions.

Treatment

Treatment varies based on infection stage and severity. Acute hepatitis B typically requires only supportive care, while chronic infection may need antiviral therapy.

Antiviral medications for chronic hepatitis B include: Tenofovir and entecavir are first-line oral nucleotide/nucleoside analogs that suppress viral replication. Interferon alfa and pegylated interferon are injectable immunomodulators used in selected patients. Lamivudine, adefovir, and telbivudine are older oral agents still used in specific situations.

Treatment goals include suppressing viral replication, reducing liver inflammation, and preventing progression to cirrhosis and liver cancer. Regular monitoring includes viral load testing, liver function assessment, and screening for hepatocellular carcinoma.

Prognosis

Prognosis varies significantly based on age at infection and disease management. Most adults (90-95%) who acquire hepatitis B recover completely and develop lifelong immunity. However, the majority of infants infected at birth (90%) and many young children (30-50%) develop chronic infection.

With appropriate antiviral treatment, people with chronic hepatitis B can achieve viral suppression in 60-80% of cases, significantly reducing the risk of liver complications. Untreated chronic hepatitis B carries a 15-25% lifetime risk of dying from cirrhosis or liver cancer. Early diagnosis and treatment can normalize life expectancy in many patients. Factors associated with better outcomes include younger age, lower viral load, minimal liver damage at diagnosis, and good adherence to antiviral therapy.

Quality of life

Living with hepatitis B requires ongoing medical care and lifestyle adjustments, but many people maintain excellent quality of life with proper management.

Lifestyle recommendations include: Avoiding alcohol completely, as it accelerates liver damage. Maintaining a healthy diet rich in fruits, vegetables, and lean proteins while limiting processed foods and excess fats. Regular exercise helps maintain healthy weight and reduces fatty liver. Adequate sleep supports immune function and liver recovery. Stress management through counseling, support groups, or relaxation techniques benefits overall health.

Social considerations: Open communication with family, partners, and healthcare providers reduces isolation and ensures proper precautions. Safe practices prevent transmission to others. Many people continue normal work and school activities with appropriate accommodations when needed. Regular medical monitoring helps catch complications early and adjust treatment as necessary.

Pregnancy and fertility

Hepatitis B can affect pregnancy outcomes and requires special management to prevent mother-to-child transmission. The infection generally does not impair fertility in men or women.

Pregnancy considerations include: All pregnant women should be tested for hepatitis B during each pregnancy. Infected mothers have up to 90% risk of transmitting the virus to their babies without preventive measures. Antiviral therapy may be recommended in the third trimester for mothers with high viral loads. Tenofovir is considered safe during pregnancy. Cesarean section is not routinely recommended solely for hepatitis B prevention.

Infants born to infected mothers should receive hepatitis B vaccine and immunoglobulin within 12 hours of birth, followed by completion of the vaccine series. Breastfeeding is safe for immunized infants.

Children

Children with hepatitis B often have no symptoms initially but require lifelong monitoring and care. Pediatric hepatitis B management focuses on preventing progression and transmission while supporting normal development.

Pediatric considerations include: Regular monitoring every 6-12 months with blood tests and imaging studies. Antiviral treatment is typically reserved for children with evidence of active liver disease. School attendance is generally unrestricted with appropriate precautions for blood exposure. Family counseling helps address concerns about transmission and stigma. Transition to adult care should begin in adolescence with comprehensive education about the condition and self-management skills.

When to see a doctor

Seek immediate medical attention for: Signs of liver failure including confusion, severe fatigue, abdominal swelling, or bleeding. Severe abdominal pain, persistent vomiting, or signs of dehydration require urgent evaluation.

Routine medical care is needed for: Known hepatitis B exposure, symptoms suggestive of hepatitis, abnormal liver function tests, or if you’re in a high-risk group requiring screening. People with chronic hepatitis B need regular monitoring every 3-6 months to assess disease activity and screen for complications.

Regional context

Hepatitis B prevalence varies across the Caucasus region, with some areas showing intermediate endemicity rates of 2-8%. Georgia has implemented comprehensive vaccination programs, significantly reducing new infections. Healthcare infrastructure improvements have enhanced diagnosis and treatment access in urban centers, though rural areas may face challenges in specialized care delivery. GMJ welcomes contributions from regional researchers to build the evidence base for hepatitis B management and outcomes in the Caucasus.

Research and clinical trials

Current research focuses on achieving functional cure rates and developing therapeutic vaccines. Novel approaches include therapeutic vaccines, immune modulators, and combination therapies targeting different aspects of viral replication and immune response.

Active research areas include: Capsid assembly modulators, entry inhibitors, and RNA interference technologies. Studies are investigating optimal treatment duration and strategies for achieving HBsAg loss. Combination therapies pairing antivirals with immunomodulators show promise in clinical trials.

Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Participation in research contributes to advancing hepatitis B treatment and potentially achieving functional cure.

Frequently asked questions

Can hepatitis B be cured?

While there is no complete cure for chronic hepatitis B, antiviral treatments can suppress the virus to undetectable levels and prevent liver damage. A small percentage of patients achieve “functional cure” with loss of surface antigen.

How contagious is hepatitis B?

Hepatitis B is highly contagious through blood and sexual contact, but it does not spread through casual contact, sharing food, or airborne transmission. Proper vaccination provides excellent protection.

Can I live a normal life with hepatitis B?

Yes, most people with hepatitis B live normal, healthy lives with appropriate medical care, lifestyle modifications, and regular monitoring. Many continue normal work, relationships, and activities.

Should family members get tested?

Yes, household contacts and sexual partners should be tested and vaccinated if not immune. Close contacts may have been exposed and need evaluation and prevention measures.

Is the hepatitis B vaccine safe?

The hepatitis B vaccine is very safe with minimal side effects, typically limited to mild pain at injection site. Serious adverse reactions are extremely rare, and benefits far outweigh risks.

Support and resources

International organizations:
– World Health Organization (WHO) Hepatitis Program: https://www.who.int/health-topics/hepatitis
– Hepatitis B Foundation: https://www.hepb.org
– World Hepatitis Alliance: https://www.worldhepatitisalliance.org
– Centers for Disease Control and Prevention: https://www.cdc.gov/hepatitis/hbv/
– European Association for the Study of the Liver: https://easl.eu

Related conditions

Hepatitis C – Another viral hepatitis infection with similar transmission routes but different treatment approaches.

Hepatitis D – A viral infection that only occurs in people already infected with hepatitis B, potentially worsening liver disease.

Liver cirrhosis – Advanced liver scarring that can result from chronic hepatitis B infection.

Hepatocellular carcinoma – Primary liver cancer strongly associated with chronic hepatitis B infection.

HIV infection – Co-infection with HIV accelerates hepatitis B progression and complicates treatment decisions.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.